We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Revance Therapeutics Inc | NASDAQ:RVNC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.2492 | 6.61% | 4.0192 | 1.33 | 4.02 | 4.07 | 3.88 | 3.92 | 1,533,475 | 05:00:07 |
Delaware
(State or other jurisdiction of incorporation or organization) |
77-0551645
(I.R.S. Employer Identification No.) |
7555 Gateway Boulevard
Newark, California 94560 (Address of Principal Executive Offices) |
94560
(Zip Code) |
Large accelerated filer
¨
|
Accelerated filer
ý
|
Non-accelerated filer
¨
(Do not check if a smaller reporting company)
|
Smaller reporting company
¨
|
Title of Securities
to be Registered |
|
Amount
to be Registered(1) |
|
Proposed
Maximum Offering Price per Share(2) |
|
Proposed
Maximum Aggregate Offering Price(2) |
|
Amount of
Registration Fee |
|||||||
Common Stock, par value $0.001 per share
|
|
|
|
|
|
|
|
|
|||||||
– 2014 Equity Incentive Plan
|
|
1,145,958
|
|
$
|
20.18
|
|
|
$
|
23,125,432.44
|
|
|
$
|
2,680.24
|
|
|
– 2014 Employee Stock Purchase Plan
|
|
286,489
|
|
$
|
20.18
|
|
|
$
|
5,781,348.02
|
|
|
$
|
670.06
|
|
|
Total
|
|
1,432,447
|
|
$
|
20.18
|
|
|
$
|
28,906,780.46
|
|
|
$
|
3,350.30
|
|
|
(1)
|
Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of Registrant’s common stock that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant’s common stock.
|
||||||||||||||
(2)
|
Estimated in accordance with Rule 457(h) and Rule 457(c) promulgated under the Securities Act solely for the purpose of calculating the registration fee. The offering price per share and the aggregate offering price are based upon the average of the high and low prices of the Registrant’s common stock as reported on the NASDAQ Global Market on February 24, 2017, in accordance with Rule 457(c) of the Securities Act.
|
Exhibit
Number |
|
Description
|
4.1(1)
|
|
Amended and Restated Certificate of Incorporation
|
4.2(2)
|
|
Amended and Restated Bylaws
|
4.3(3)
|
|
Specimen Stock Certificate
|
4.4(4)
|
|
Revance Therapeutics, Inc. 2014 Equity Incentive Plan
|
4.5(5)
|
|
Form of Restricted Stock Unit Award Agreement and Grant Notice for Revance Therapeutics, Inc. 2014 Equity Incentive Plan
|
4.6(6)
|
|
Form of Stock Option Agreement and Grant Notice for Revance Therapeutics, Inc. 2014 Equity Incentive Plan
|
4.7(7)
|
|
Form of Restricted Stock Bonus Agreement and Grant Notice for Revance Therapeutics, Inc. 2014 Equity Incentive Plan
|
4.8(8)
|
|
Revance Therapeutics, Inc. 2014 Employee Stock Purchase Plan
|
5.1
|
|
Opinion of Cooley LLP
|
23.1
|
|
Consent of Independent Registered Public Accounting Firm
|
23.2
|
|
Consent of Cooley LLP. Reference is made to Exhibit 5.1 to this Registration Statement
|
24.1
|
|
Power of Attorney. Reference is made to the signature page of this Registration Statement
|
|
(1)
|
Filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36297), filed with the SEC on February 11, 2014, and incorporated by reference herein.
|
(2)
|
Filed as Exhibit 3.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-193154), filed with the SEC on December 31, 2013, and incorporated by reference herein.
|
(3)
|
Filed as Exhibit 4.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-193154), filed with the SEC on February 3, 2014, and incorporated by reference herein.
|
(4)
|
Filed as Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1 (File No. 333-193154), filed with the SEC on January 27, 2014, and incorporated by reference herein.
|
(5)
|
Filed as Exhibit 10.6 to the Registrant’s Annual Report on Form 10-K (File No. 001-36297), filed with the SEC on March 4, 2016, and incorporated by reference herein.
|
(6)
|
Filed as Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-36297), filed with the SEC on November 10, 2015, and incorporated by reference herein.
|
(7)
|
Filed as Exhibit 10.8 to the Registrant’s Annual Report on Form 10-K (File No. 001-36297), filed with the SEC on March 4, 2016, and incorporated by reference herein.
|
(8)
|
Filed as Exhibit 10.7 to the Registrant’s Registration Statement on Form S-1 (File No. 333-193154), filed with the SEC on January 27, 2014, and incorporated by reference herein.
|
REVANCE THERAPEUTICS, INC.
|
||
|
|
|
By:
|
|
/s/ L. Daniel Browne
|
|
|
L. Daniel Browne
|
|
|
President and Chief Executive Officer
|
Signature
|
Title
|
Date
|
|
|
|
/s/ L. Daniel Browne
|
President, Chief Executive
|
February 28, 2017
|
L. Daniel Browne
|
Officer and Director
|
|
|
(Principal Executive Officer)
|
|
|
|
|
/s/ Lauren P. Silvernail
|
Chief Financial Officer and
|
February 28, 2017
|
Lauren P. Silvernail
|
Chief Business Officer
|
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
/s/ Angus C. Russell
|
Director, Chairman
|
February 28, 2017
|
Angus C. Russell
|
|
|
|
|
|
/s/ Robert Byrnes
|
Director
|
February 28, 2017
|
Robert Byrnes
|
|
|
|
|
|
/s/ Ronald W. Eastman
|
Director
|
February 28, 2017
|
Ronald W. Eastman
|
|
|
|
|
|
/s/ Phyllis Gardner
|
Director
|
February 28, 2017
|
Phyllis Gardner, M.D.
|
|
|
Signature
|
Title
|
Date
|
|
|
|
/s/ Julian S. Gangolli
|
Director
|
February 28, 2017
|
Julian S. Gangolli
|
|
|
|
|
|
/s/ Mark A. Prygocki, Sr.
|
Director
|
February 28, 2017
|
Mark A. Prygocki, Sr.
|
|
|
|
|
|
/s/ Philip J. Vickers
|
Director
|
February 28, 2017
|
Philip J. Vickers, Ph.D.
|
|
|
Exhibit
Number |
|
Description
|
4.1(1)
|
|
Amended and Restated Certificate of Incorporation
|
4.2(2)
|
|
Amended and Restated Bylaws
|
4.3(3)
|
|
Specimen Stock Certificate
|
4.4(4)
|
|
Revance Therapeutics, Inc. 2014 Equity Incentive Plan
|
4.5(5)
|
|
Form of Restricted Stock Unit Award Agreement and Grant Notice for Revance Therapeutics, Inc. 2014 Equity Incentive Plan
|
4.6(6)
|
|
Form of Stock Option Agreement and Grant Notice for Revance Therapeutics, Inc. 2014 Equity Incentive Plan
|
4.7(7)
|
|
Form of Restricted Stock Bonus Agreement and Grant Notice for Revance Therapeutics, Inc. 2014 Equity Incentive Plan
|
4.8(8)
|
|
Revance Therapeutics, Inc. 2014 Employee Stock Purchase Plan
|
5.1
|
|
Opinion of Cooley LLP
|
23.1
|
|
Consent of Independent Registered Public Accounting Firm
|
23.2
|
|
Consent of Cooley LLP. Reference is made to Exhibit 5.1 to this Registration Statement
|
24.1
|
|
Power of Attorney. Reference is made to the signature page of this Registration Statement
|
|
(1)
|
Filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36297), filed with the SEC on February 11, 2014, and incorporated by reference herein.
|
(2)
|
Filed as Exhibit 3.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-193154), filed with the SEC on December 31, 2013, and incorporated by reference herein.
|
(3)
|
Filed as Exhibit 4.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-193154), filed with the SEC on February 3, 2014, and incorporated by reference herein.
|
(4)
|
Filed as Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1 (File No. 333-193154), filed with the SEC on January 27, 2014, and incorporated by reference herein.
|
(5)
|
Filed as Exhibit 10.6 to the Registrant’s Annual Report on Form 10-K (File No. 001-36297), filed with the SEC on March 4, 2016, and incorporated by reference herein.
|
(6)
|
Filed as Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-36297), filed with the SEC on November 10, 2015, and incorporated by reference herein.
|
(7)
|
Filed as Exhibit 10.8 to the Registrant’s Annual Report on Form 10-K (File No. 001-36297), filed with the SEC on March 4, 2016, and incorporated by reference herein.
|
(8)
|
Filed as Exhibit 10.7 to the Registrant’s Registration Statement on Form S-1 (File No. 333-193154), filed with the SEC on January 27, 2014, and incorporated by reference herein.
|
1 Year Revance Therapeutics Chart |
1 Month Revance Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions